← 返回列表 › SCI 期刊 › 医学 › BLOOD ADV

Blood Advances

BLOOD ADV

Print ISSN 2473-9529 Online ISSN 2473-9537
SCIE Q1 新锐1区 Top期刊 开放获取 医学
影响因子 2026
7.7
↑ 0.6
5年均分
7.2
5-Year IF
H 指数
130
H-Index
年发文量
735
Articles / Year
出刊频率
Continuously Published
Pub. Frequency
创刊年份
1920
Founded Year
出版商
Elsevier
Publisher
出版国家
USA
Country
投稿参考 & 用户评分
🏆 期刊声誉
★★★★★
暂无
综合口碑评分,点击星星参与
⚡ 审稿速度
★★★★★
系统
暂无
约 3.7 个月
💰 版面费用
★★★★★
系统
暂无
官方APC $3,000 USD 约¥21,750
中科院分区
2026新锐分区 新体系
大类1区
医学Medicine
小类2区
血液学Hematology
中科院2025年分区 传统体系
大类1区
医学Medicine
小类2区
血液学Hematology
WoS 期刊 JCR 分区 (2026 · JIF) 综合 SCIE Q1
学科 收录集 JIF 分区 JIF 排名 JIF 百分位
血液学 Hematology SCIE Q1 13/103
87.4%
按 JCI 指标学科分区
学科 收录集 JCI 分区 JCI 排名 JCI 百分位
血液学 Hematology SCIE Q1 11/87 JCI 1.74
88.5%
Scopus 指标
CiteScore
11.8
综合引用得分
SJR
3.110 Q1
SCImago Journal Rank
SNIP
1.750
Source Normalized Impact
JCI
1.74
Journal Citation Indicator
数据来源:Scopus (CiteScore · SJR · SNIP) · Clarivate (JCI)。指标年份:2026年6月最新版。
期刊简介

Blood Advances is a prestigious, peer-reviewed, open-access medical journal published by the American Society of Hematology (ASH). With an ISSN of 2473-9529 and an abbreviation of BLOOD ADV, the journal serves as a vital complement to its flagship title, *Blood*, by focusing on the rapid dissemination of high-quality original research in hematology. Its scope encompasses the full spectrum of benign and malignant hematologic disorders, including hemostasis and thrombosis, red cell biology, hematologic malignancies, transfusion medicine, stem cell transplantation, and gene therapy. The journal publishes original Articles, Review Articles, and Brief Reports, with a strong emphasis on translational and clinical research that directly advances patient care. The target audience includes hematologists, oncologists, basic scientists, clinical researchers, and allied health professionals dedicated to blood disorders. A defining feature is its open-access model, ensuring that all content is freely and immediately available to the global scientific community, thereby maximizing the reach and impact of published findings. As of 2026, *Blood Advances* holds an impressive Journal Citation Reports (JCR) Impact Factor of 7.700 and is ranked in the Q1 quartile, placing it among the top-tier journals in the field of hematology. This standing, combined with its rigorous peer review and association with ASH, establishes the journal as an authoritative and highly influential platform for the most current and significant advances in blood science and clinical practice.

历年影响因子 & 年发文量

上述信息均来源于网络,以官方发布为准,仅供参考。如有建议,欢迎反馈

生物行 © 2002–2026  All Rights Reserved.